Omeprazole

Overview

Omeprazole, sold under the brand names Prilosec and Losec among others, is a medication used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton-pump inhibitor (PPI) and its effectiveness is similar to that of other PPIs. It can be taken by mouth or by injection into a vein. It is also available in the fixed-dose combination medication omeprazole/sodium bicarbonate as Zegerid and as Konvomep.[1–6] WP

Common side effects include nausea, vomiting, headaches, abdominal pain, and increased intestinal gas. Serious side effects may include Clostridioides difficile colitis, an increased risk of pneumonia, an increased risk of bone fractures, and the potential of masking stomach cancer. Whether it is safe for use in pregnancy is unclear. It works by blocking the release of stomach acid.[1][7] WP

Omeprazole was patented in 1978 and approved for medical use in 1988. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the tenth most commonly prescribed medication in the United States, with more than 45 million prescriptions. It is also available without a prescription in the United States.[1][8–15] WP

Uses, dosage and effects

Medical uses

Omeprazole can be used in the treatment of gastroesophageal reflux disease (GERD), heartburn, peptic ulcers, erosive esophagitis, Zollinger–Ellison syndrome, and eosinophilic esophagitis.[1][16] WP

Peptic ulcers

Peptic ulcers may be treated with omeprazole. Infection with Helicobacter pylori can be treated by taking omeprazole, amoxicillin, and clarithromycin together for 7–14 days. Amoxicillin may be replaced with metronidazole in patients who are allergic to penicillin.[17][18] WP

Long-term use

Long-term use of PPIs is strongly associated with the development of benign polyps from fundic glands (which is distinct from fundic gland polyposis); these polyps do not cause cancer and resolve when PPIs are discontinued. No association is seen between PPI use and cancer, but use of PPIs may mask gastric cancers or other serious gastric problems.[19] WP

There is a possible association between long-term use and dementia which requires further study to confirm.[20] WP

An article published in 2013 claims that the long-term use of PPIs is associated with decreased calcium absorption (causing increased risk of osteoporosis and fractures), decreased magnesium absorption (causing electrolyte disturbances), and increased risk of certain infections, such as C. difficile and community-acquired pneumonia. The authors hypothesize that this is due to decreased stomach acid production.[21] WP

Veterinary uses

In February 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Omeprazole TriviumVet, gastro-resistant capsule, hard, intended for dogs. The applicant for this veterinary medicinal product is TriviumVet DAC. Omeprazole TriviumVet was authorized for veterinary use in the European Union in April 2025.[22][23] WP

Risks and side effects

Adverse effects

Adverse effects occurring in at least 1% of people include:[24] WP⚠ Wikipedia itself has flagged this text: failed verification.

• Central nervous system: headache (7%), dizziness (2%)[24] WP
• Respiratory: upper respiratory tract infection (2%), cough (1%)[24] WP
• Gastrointestinal: abdominal pain (5%), diarrhea (4%), nausea (4%), vomiting (3%), flatulence (3%), acid regurgitation (2%), constipation (2%)[24] WP
• Neuromuscular and skeletal: back pain (1%), weakness (1%)[24] WP
• Dermatologic: rash (2%)[24] WP

Other concerns related to adverse effects are: WP

• Recurrence of Clostridioides difficile associated diarrhea[25] WP
• Osteoporosis-related fractures[26][27] WP
• Hypomagnesemia[28] WP

Concern has been expressed regarding vitamin B₁₂ and iron malabsorption, but effects seem to be insignificant, especially when supplement therapy is provided.[29][30][31] WP

Since their introduction, proton-pump inhibitors (PPIs, especially omeprazole) have also been associated with several cases of acute interstitial nephritis, an inflammation of the kidneys that often occurs as an adverse drug reaction.[32] WP

Pregnancy and breastfeeding

The safety of using omeprazole has not been established in pregnant or breastfeeding women. Epidemiological data do not show an increased risk of major birth defects after maternal use of omeprazole during pregnancy.[7][33] WP

Interactions

Interactions

Important drug interactions are rare. However, the most significant major drug interaction concern is the decreased activation of clopidogrel when taken together with omeprazole. Although still controversial, this may increase the risk of stroke or heart attack in people taking clopidogrel to prevent these events.[34–37] WP

This interaction is possible because omeprazole is an inhibitor of the enzymes CYP2C19 and CYP3A4. Clopidogrel is an inactive prodrug that partially depends on CYP2C19 for conversion to its active form. Inhibition of CYP2C19 may block the activation of clopidogrel, which could reduce its effects.[38][39][40] WP

Almost all benzodiazepines are metabolised by the CYP3A4 and CYP2D6 pathways, and inhibition of these enzymes results in a higher area under the curve (i.e., the total effect over time of a given dose). Other examples of drugs dependent on CYP3A4 for their metabolism are escitalopram, warfarin, oxycodone, tramadol, and oxymorphone. The concentrations of these drugs may increase if they are used concomitantly with omeprazole.[41][42][43] WP

Omeprazole is also a competitive inhibitor of p-glycoprotein, as are other PPIs.[44] WP

Drugs that depend on an acidic stomach environment (such as ketoconazole or atazanavir) may be poorly absorbed, whereas acid-labile antibiotics (such as erythromycin which is a very strong CYP3A4 inhibitor) may be absorbed to a greater extent than normal due to the more alkaline environment of the stomach.[43] WP

St. John's wort (Hypericum perforatum) and Ginkgo biloba significantly reduce plasma concentrations of omeprazole through induction of CYP3A4 and CYP2C19.[45] WP

Pharmacology

Pharmacology

Omeprazole irreversibly blocks the enzyme system on parietal cells that is needed for the secretion of gastric acid. It is a specific H⁺/K⁺ATPase inhibitor. This is the enzyme needed for the final step in the secretion of gastric acid.[46] WP

Pharmacokinetics

The absorption of omeprazole takes place in the small intestine and is usually completed within three to six hours. The systemic bioavailability of omeprazole after repeated doses is about 60%. Omeprazole has a volume of distribution of 0.4 L/kg. It has high plasma protein binding of 95%.[47][48] WP

Omeprazole is completely metabolized by the cytochrome P450 system, mainly in the liver, by CYP2C19 and CYP3A4 isoenzymes. Identified metabolites are the sulfone, the sulfide, and hydroxy-omeprazole. About 77% of an orally given dose is excreted as metabolites in the urine, and the remainder is found in the feces, primarily originating from bile secretion. Omeprazole has a half life of 0.5 to 1 hour.[7][49] WP

Bioactivation

As with all structurally-similar benzimidazole proton pump inhibitors, omeprazole is a prodrug. A basic molecule, it accumulates in the acidic canaliculi of parietal cells in a protonated form where the S=O group becomes S-OH, which in turn is interconvertible with an achiral, reactive sulfenamide form. The sulfenamide form is able to attach onto the cysteine residue on the H⁺/K⁺-ATPase, thereby irreversibly inhibiting it.[50] WP

Chirality

The two different chiralities of omeprazole are both metabolized into inactive products by cytochrome P450 enzymes, but each chirality is differently inactivated by specific isozymes. Compared to the (R)-enantiomer, the (S)-enantiomer is relatively more resistant to metabolism, especially metabolism by CYP2C19 (if it's processed by CYP2C19 at all). As a result, among people with a more active version of CYP2C19 ("extensive metabolizers"), the (R) half of a dose of omeprazole is likely to perform more poorly. Conversely, among those with a less active version of CYP2C19 ("poor metabolizers"), more the (R) half is expected to survive metabolism and end up useful. The proportion of the poor metabolizer phenotype varies widely between populations, from 2.0 to 2.5% in African Americans and white Americans to >20% in Asians. Several pharmacogenomics studies have suggested that PPI treatment should be tailored according to CYP2C19 metabolism status.[51][52][53] WP

AstraZeneca also developed esomeprazole (Nexium) which is a eutomer, purely the (S)-enantiomer, rather than a racemate like omeprazole.[54] WP

Mechanism of action

Omeprazole is a selective and irreversible proton pump inhibitor. It suppresses stomach acid secretion by specific inhibition of the H⁺/K⁺-ATPase system found at the secretory surface of gastric parietal cells. Because this enzyme system is regarded as the acid (proton, or H⁺) pump within the gastric mucosa, omeprazole inhibits the final step of acid production.[46] WP

Omeprazole also inhibits both basal and stimulated acid secretion irrespective of the stimulus as it blocks the last step in acid secretion. The drug binds non-competitively so it has a dose-dependent effect.[48][49] WP

The inhibitory effect of omeprazole occurs within one hour after oral administration. The maximum effect occurs within two hours. The duration of inhibition is up to 72 hours. When omeprazole is stopped, baseline stomach acid secretory activity returns after three to five days. The inhibitory effect of omeprazole on acid secretion will plateau after four days of repeated daily dosing.[55] WP

Omeprazole is only effective on active H⁺/K⁺-ATPase pumps. These pumps are stimulated in the presence of food to aid in digestion.[56] WP

History

History

Omeprazole was first made in 1979 by Swedish AB Hässle, part of Astra AB. It was the first of the proton pump inhibitors (PPI). Astra AB, now AstraZeneca, launched it as an ulcer medicine under the name Losec in Sweden. It was first sold in the United States in 1989 under the brand name Losec. In 1990, at the request of the US Food and Drug Administration, the brand name Losec was changed to Prilosec to avoid confusion with the diuretic Lasix (furosemide). The new name led to confusion between omeprazole (Prilosec) and fluoxetine (Prozac), an antidepressant. Prilosec is owned by Procter & Gamble in alliance with AstraZeneca and the product is designed to address frequent heartburn, which can be triggered by various factors such as certain foods, stress, and smoking.[57–60] WP

Prilosec was first introduced in 1989 as a prescription medication approved by the FDA for the treatment of severe heartburn. In 2003, Prilosec OTC was launched as the first over-the-counter option for managing frequent heartburn. It is known for its advertising campaign featuring Larry the Cable Guy as the spokesperson for the brand, during the 2010s, emphasizing the concept of "Zero Heartburn".[14][61][62] WP

Legal status

Economics

When Prilosec's US patent expired in April 2001, AstraZeneca introduced esomeprazole (Nexium) as a patented replacement drug. Many companies introduced generics as AstraZeneca's patents expired worldwide, which are available under many brand names.[63] WP

Omeprazole was a subject of a patent litigation in the U.S. The invention involved application of two different coatings to a drug in pill form to ensure that the omeprazole did not disintegrate before reaching its intended site of action in the stomach. Although the solution by means of two coatings was obvious, the patent was found valid, because the source of the problem was non-obvious and was discovered by the patentee.[64][65] WP

In September 2023, AstraZeneca announced it would pay $425 million to settle product liability litigations against Prilosec in the United States.[66] WP

Brand names

Brand names include Losec, Prilosec, Zegerid, Miracid, and Omez.[1][67] WP

Chemistry

Formula

C17H19N3O3S PC

CAS number

73590-58-6 PC

Molar mass (g/mol)

345.4 PC

IUPAC name (computed by PubChem)

6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole PC

SMILES

CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC PC

InChIKey

SUBDBMMJDZJVOS-UHFFFAOYSA-N PC

PubChem CID

4594

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Omeprazole
2. Other 99 Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative. 28 June 2016
3. Other Omeprazole 40 mg Powder for Solution for Infusion. 10 February 2016
4. Journal / agency Zegerid- omeprazole and sodium bicarbonate powder, for suspension Zegerid- omeprazole and sodium bicarbonate capsule. 4 March 2022
5. Journal / agency Zegerid OTC- omeprazole and sodium bicarbonate capsule, gelatin coated. 5 December 2022
6. Journal / agency Konvomep- omeprazole and sodium bicarbonate kit. 30 August 2022
7. Other Vallerand AH, Sanoski CA, Deglin JH. Davis's Drug Guide for Nurses. 2015
8. Other Lagercrantz, Samuel. The stomach medication that became the biggest blockbuster of the 1990s. 29 November 2022
9. Journal / agency Product Details for NDA 019810. 5 October 1995
10. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
11. Other The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
12. Other The Top 300 of 2023
13. Other Omeprazole Drug Usage Statistics, United States, 2014 - 2023
14. Journal / agency Questions and Answers on Prilosec OTC (omeprazole). 3 November 2018
15. Journal / agency Drug Approval Package: Prilosec (Omeprazole Magnesium) NDA #021229
16. Journal / agency Cheng E. Proton pump inhibitors for eosinophilic oesophagitis. Current Opinion in Gastroenterology. July 2013. doi:10.1097/MOG.0b013e32835fb50e · PMID 23449027 · PMC4118554
17. Journal / agency Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Annals of Internal Medicine. October 2007. doi:10.7326/0003-4819-147-8-200710160-00008 · PMID 17938394
18. Journal / agency Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. June 2007. doi:10.1136/gut.2006.101634 · PMID 17170018 · PMC1954853
19. Journal / agency Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Current Opinion in Endocrinology, Diabetes, and Obesity. February 2014. doi:10.1097/med.0000000000000031 · PMID 24310148
20. Journal / agency Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use. Journal of Gastroenterology and Hepatology. July 2017. doi:10.1111/jgh.13737 · PMID 28092694
21. Journal / agency O'Neill LW, Culpepper BL, Galdo JA. Long-Term Consequences of Chronic Proton Pump Inhibitor Use. US Pharmacist. December 2013
22. Journal / agency Omeprazole TriviumVet EPAR. 12 February 2025
23. Other Omeprazole TriviumVet PI. 3 April 2025
24. Journal / agency McTavish D, Buckley MM, Heel RC. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs. July 1991. doi:10.2165/00003495-199142010-00008 · PMID 1718683
25. Journal / agency Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLOS ONE. June 2014. doi:10.1371/journal.pone.0098400 · PMID 24897375 · PMC4045753
26. Journal / agency Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. December 2006. doi:10.1001/jama.296.24.2947 · PMID 17190895
27. Journal / agency Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. The American Journal of Medicine. June 2011. doi:10.1016/j.amjmed.2011.01.007 · PMID 21605729 · PMC3101476
28. Journal / agency Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Alimentary Pharmacology & Therapeutics. September 2012. doi:10.1111/j.1365-2036.2012.05201.x · PMID 22762246
29. Journal / agency Neal K, Logan R. Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Alimentary Pharmacology & Therapeutics. July 2001. doi:10.1046/j.1365-2036.2001.0994a.x · PMID 11421886
30. Journal / agency Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Digestive Diseases and Sciences. August 2011. doi:10.1007/s10620-011-1589-y · PMID 21318590
31. Journal / agency McColl KE. Effect of proton pump inhibitors on vitamins and iron. The American Journal of Gastroenterology. March 2009. doi:10.1038/ajg.2009.45 · PMID 19262546
32. Journal / agency Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. British Journal of Clinical Pharmacology. December 2007. doi:10.1111/j.1365-2125.2007.02927.x · PMID 17635502 · PMC2198775
33. Journal / agency Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. The New England Journal of Medicine. November 2010. doi:10.1056/NEJMoa1002689 · PMID 21105793
34. Other Fitzakerley J. 2014 Treatments for Acid-Peptic Diseases
35. Other Proton Pump Inhibitor: Use in Adults
36. Journal / agency Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, Smeeth L. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ. July 2012. doi:10.1136/bmj.e4388 · PMID 22782731 · PMC3392956
37. Journal / agency Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart. April 2013. doi:10.1136/heartjnl-2012-302371 · PMID 22851683
38. Journal / agency Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metabolism and Disposition. July 2013. doi:10.1124/dmd.113.051722 · PMID 23620487 · PMC3684819
39. Journal / agency Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ. March 2009. doi:10.1503/cmaj.090251 · PMID 19332744 · PMC2659824
40. Journal / agency Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. The Annals of Pharmacotherapy. July 2009. doi:10.1345/aph.1M051 · PMID 19470853
41. Other Selective Serotonin Reuptake Inhibitors and CYP2D6
42. Journal / agency Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. May 2003. doi:10.1097/00008571-200305000-00002 · PMID 12724615
43. Journal / agency Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology & Therapeutics. August 2000. doi:10.1046/j.1365-2036.2000.00788.x · PMID 10930890
44. Journal / agency Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's Archives of Pharmacology. December 2001. doi:10.1007/s00210-001-0489-7 · PMID 11770010
45. Journal / agency Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009. doi:10.2165/11317010-000000000-00000 · PMID 19719333
46. Journal / agency Howden CW. Clinical pharmacology of omeprazole. Clinical Pharmacokinetics. January 1991. doi:10.2165/00003088-199120010-00003 · PMID 2029801
47. Journal / agency Cederberg C, Andersson T, Skånberg I. Omeprazole: pharmacokinetics and metabolism in man. Scandinavian Journal of Gastroenterology. Supplement. January 1989. doi:10.3109/00365528909091241 · PMID 2690330
48. Journal / agency Clissold SP, Campoli-Richards DM. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. July 1986. doi:10.2165/00003495-198632010-00002 · PMID 3527658
49. Harm reduction site Omeprazole
50. Journal / agency Huttunen KM, Raunio H, Rautio J. Prodrugs--from serendipity to rational design. Pharmacological Reviews. September 2011. doi:10.1124/pr.110.003459 · PMID 21737530
51. Journal / agency Roche VF. The chemically elegant proton pump inhibitors. American Journal of Pharmaceutical Education. October 2006. doi:10.5688/aj7005101 · PMID 17149430 · PMC1637016
52. Journal / agency Shiohira H, Yasui-Furukori N, Yamada S, Tateishi T, Akamine Y, Uno T. Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes. Pharmaceutical Research. August 2012. doi:10.1007/s11095-012-0757-x · PMID 22549736
53. Journal / agency Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metabolism and Pharmacokinetics. June 2005. doi:10.2133/dmpk.20.153 · PMID 15988117
54. Journal / agency Nexium- esomeprazole magnesium capsule, delayed release; Nexium- esomeprazole magnesium granule, delayed release. 18 July 2023
55. Journal / agency Omeprazole package insert. June 2013
56. Journal / agency Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology. March 2013. doi:10.1038/ajg.2012.444 · PMID 23419381
57. Journal / agency Trends in Drug Patenting - Case Studies: THE CASES: 5. OMEPRAZOLE
58. Journal / agency Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand SE, Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature. March 1981. doi:10.1038/290159a0 · PMID 6259537
59. Journal / agency Farley D. Making it easier to read prescriptions. FDA Consumer. July–August 1995. PMID 10143448
60. Other AstraZeneca/P&G's Prilosec OTC cleared by FDA for frequent heartburn
61. Journal / agency Research, Center for Drug Evaluation and. Prilosec OTC (omeprazole) Information. FDA. 2018-11-03
62. Other Hummingbird Productions. Prilosec OTC w/ Larry the Cable Guy. 2013-07-19
63. Other Harris G. Prilosec's Maker Switches Users to Nexium, Thwarting Generics. 6 June 2002
64. Other AstraZeneca awarded damages in Prilosec patent litigation. 3 December 2013
65. Other IN RE OMEPRAZOLE PATENT LITIGATION, Court of Appeals, Federal Circuit 2011
66. Other AstraZeneca to pay $425 mln to settle Nexium, Prilosec litigation in US. 3 October 2023
67. Other Omeprazole international. 3 February 2020

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.